Sanofi has returned to Nurix Therapeutics for another autoimmune candidate, paying $15 million and committing up to $465 ...

Nurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive ...

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 programNurix DEL-AI drug ...

Nurix Therapeutics (NRIX) announced that Sanofi (SNY) has exclusively licensed an undisclosed Nurix program targeting a previously undruggable ...

US clinical-stage biotech Nurix Therapeutics (Nasdaq: NRIX) announced that Sanofi (Euronext: SAN) has exclusively licensed an ...

Nurix Therapeutics has widened its collaboration with Sanofi, granting the French pharmaceutical company an exclusive license to an undisclosed program targeting a previously undruggable transcription ...

Sanofi pays $15M to license Nurix autoimmune program. Sumitomo transfers Asia units. Gilead cuts 149 jobs, Roche 108 in ...

Nurix Therapeutics, Inc.’s NRIX share price has dipped by 11.87%, which has investors questioning if this is right time to buy.

Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates.

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Nurix is advancing its clinical pipeline ... The company also maintains collaborative drug discovery efforts with Gilead Sciences, Sanofi S.A., and Pfizer Inc., retaining co-development and ...

Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., ...